Allergic Rhinitis, Asthma
Conditions
Keywords
Air contamination, Air pollutants, Non-communicable respiratory diseases, Climate change, ClimAIr
Brief summary
The ClimAIr project will expand the evidence-based understanding of climate change, air pollution, and non-communicable respiratory diseases by using Artificial Intelligence (AI) tools. It will gather data on greenhouse gases levels and disaster risks, information on serious air pollutants and respiratory diseases' prevalence. The AI powered tools will be employed to generate better intervention methods and improve public health outcomes. Federated Learning (FL) will be used to develop AI models to protect patients' privacy. By raising public awareness and delivering the ClimAIr tool - specifically designed to health workers, urban planners and policy makers - the project aims to influence policy decisions, promote healthier environments, and reduce respiratory diseases in Europe, which will be tested and validated the ClimAIr tool in specific municipalities that are part of the project. ClimAIr draws on a consortium of 21 partners from 15 European countries, including carefully selected health centres across Europe - in Spain, Luxembourg, Ukraine, Italy, France, Germany, Greece, Romania and Poland - focused on respiratory diseases, which will provide disease data and explore metabolic routes of the studied contaminants/diseases. ClimAIr is composed of an interdisciplinary team formed by research centres, ethical AI and modelling experts, SSH specialists, municipal governance, and a Communication & Dissemination (C&D) expert team dedicated to achieving and spread the results of the project.
Interventions
None listed
Sponsors
Theramed Healthcare SRL (Romania)
Centre Hospitalier Universitaire de Toulouse, FRANCE
Charite-Universitaetsmedizin Berlin (Germany)
Aristotelio Panepistimio Thessalonikis (Greece)
Uniwersytet Medyczny w Lodzi (Poland)
Universita degli Studi di Milano (Italy)
Bukovinian State Medical University (Ukraine)
Luxembourg Institute of Health (Luxembourg)
Andaluz Health Service
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Study design
Observational model
OTHER
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients with health insurance based in Malaga, Milan, Luxembourg, Thessalonikki, Lodz, Berlin, Toulousse, Chervnivtsi and Brasov (the places where environmental/climate information will be obtained from, only one recruitment place for partner). 2. 3-year history of chronic rhinitis symptoms during the corresponding pollen season, while residing in the same household AND attending the same school/college or holding the same job position. 3. Positive SPT and serum allergen-specific IgE \>0.35 kUA/L. The pollen species driving the nasal symptoms will be Olea europaea, Phleum pratense or Betula pendula. 4. Patients can be sensitized to other aeroallergens if the nasal symptoms occur exclusively or aggravate unequivocally during the pollen season of the three allergens of interest.
Exclusion criteria
Lack of reliable information in e-health records, allergen immunotherapy (any allergen) during the previous 5 years, systemic immunosuppressants or biologicals in the previous six months, chronic rhinosinusitis, and severe systemic conditions.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean Symptom Score of Allergic Rhinitis Patients by Environmental Exposure | Retrospective data collected over a 3-year period prior to study enrollment. | Mean allergic rhinitis symptom scores retrieved from electronic health records (EHR), stratified by environmental exposure levels (pollutants and climate factors), using the Observational Medical Outcomes Partnership (OMOP) common data model. |
| Proteomic Biomarker Levels (NPX) by Environmental Exposure | Samples collected prospectively between months 10 and 15 (October-March, out-of-pollen season). | Proteomic profiles measured using Olink® assays in serum and nasal lavage of allergic rhinitis patients, stratified by environmental exposure. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| SO1: Effect of air pollution on adaptive immune responses to allergenic pollen | Sample collection and analysis performed prospectively between months 10 and 24. | Evaluation of the immune response of peripheral blood mononuclear cells (PBMCs) from allergic rhinitis patients exposed to different environmental conditions, after in vitro stimulation with pollen samples previously exposed to varying pollution levels. The response will be characterized by proliferation of allergen-specific lymphocyte subsets and cytokine production. |
| SO1: Proliferative responses of allergen-specific lymphocytes to pollen exposed to pollution | Assays conducted on samples collected between months 10 and 24. | Measurement of lymphocyte proliferation using CFSE-labeled PBMCs incubated with pollen (Olea europaea, Phleum pratense, Betula pendula) grown under different pollution conditions. |
| SO1: Cytokine release from allergen-specific lymphocytes in response to polluted pollen | Analysis performed between months 10 and 24, post-sample collection. | Quantification of cytokines released in the supernatants of PBMC cultures stimulated with pollen under different pollution conditions. A multiplex ELISA panel will be used to measure Th1, Th2, Th9, and regulatory cytokine |
Contacts
Primary ContactIbon Eguiluz Gracia, MD, PhD
Outcome results
None listed